vs
Side-by-side financial comparison of Roivant Sciences Ltd. (ROIV) and Revolution Medicines, Inc. (RVMD). Click either name above to swap in a different company.
Revolution Medicines, Inc. produced more free cash flow last quarter ($-139.5M vs $-201.4M). Over the past eight quarters, Roivant Sciences Ltd.'s revenue compounded faster (-73.7% CAGR vs -100.0%).
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."
ROIV vs RVMD — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $2.0M | $0 |
| Net Profit | $-265.9M | $-194.6M |
| Gross Margin | — | — |
| Operating Margin | -16966.1% | — |
| Net Margin | -13301.2% | — |
| Revenue YoY | -77.8% | — |
| Net Profit YoY | -257.0% | -20.4% |
| EPS (diluted) | $-0.38 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.0M | — | ||
| Q3 25 | $1.6M | — | ||
| Q2 25 | $2.2M | — | ||
| Q1 25 | $-39.6M | — | ||
| Q4 24 | $9.0M | $0 | ||
| Q3 24 | $4.5M | $0 | ||
| Q2 24 | $8.0M | $0 | ||
| Q1 24 | $28.9M | $0 |
| Q4 25 | $-265.9M | — | ||
| Q3 25 | $-113.5M | — | ||
| Q2 25 | $-223.4M | — | ||
| Q1 25 | $-206.5M | — | ||
| Q4 24 | $169.4M | $-194.6M | ||
| Q3 24 | $-230.2M | $-156.3M | ||
| Q2 24 | $95.3M | $-133.2M | ||
| Q1 24 | $-151.1M | $-116.0M |
| Q4 25 | -16966.1% | — | ||
| Q3 25 | -19492.9% | — | ||
| Q2 25 | -13130.0% | — | ||
| Q1 25 | 674.8% | — | ||
| Q4 24 | -3042.6% | — | ||
| Q3 24 | -7636.0% | — | ||
| Q2 24 | -1279.5% | — | ||
| Q1 24 | -919.5% | — |
| Q4 25 | -13301.2% | — | ||
| Q3 25 | -7225.9% | — | ||
| Q2 25 | -10292.9% | — | ||
| Q1 25 | 521.8% | — | ||
| Q4 24 | 1878.3% | — | ||
| Q3 24 | -5143.8% | — | ||
| Q2 24 | 1192.7% | — | ||
| Q1 24 | -522.3% | — |
| Q4 25 | $-0.38 | — | ||
| Q3 25 | $-0.17 | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.28 | — | ||
| Q4 24 | $0.23 | $-1.13 | ||
| Q3 24 | $-0.31 | $-0.94 | ||
| Q2 24 | $0.12 | $-0.81 | ||
| Q1 24 | $-0.02 | $-0.70 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.5B | $2.3B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.3B | $2.3B |
| Total Assets | $5.2B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.5B | — | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.5B | — | ||
| Q1 25 | $4.9B | — | ||
| Q4 24 | $5.1B | $2.3B | ||
| Q3 24 | $5.4B | $1.5B | ||
| Q2 24 | $5.7B | $1.6B | ||
| Q1 24 | $6.5B | $1.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $311.7M | — | ||
| Q1 24 | $430.6M | — |
| Q4 25 | $4.3B | — | ||
| Q3 25 | $4.4B | — | ||
| Q2 25 | $4.3B | — | ||
| Q1 25 | $4.7B | — | ||
| Q4 24 | $5.2B | $2.3B | ||
| Q3 24 | $5.2B | $1.6B | ||
| Q2 24 | $5.4B | $1.6B | ||
| Q1 24 | $6.0B | $1.7B |
| Q4 25 | $5.2B | — | ||
| Q3 25 | $5.1B | — | ||
| Q2 25 | $5.0B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $5.8B | $2.6B | ||
| Q3 24 | $6.2B | $1.8B | ||
| Q2 24 | $6.5B | $1.8B | ||
| Q1 24 | $7.2B | $1.9B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.06× | — | ||
| Q1 24 | 0.07× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-196.5M | $-138.3M |
| Free Cash FlowOCF − Capex | $-201.4M | $-139.5M |
| FCF MarginFCF / Revenue | -10076.0% | — |
| Capex IntensityCapex / Revenue | 246.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-776.7M | $-567.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-196.5M | — | ||
| Q3 25 | $-185.7M | — | ||
| Q2 25 | $-204.4M | — | ||
| Q1 25 | $-172.6M | — | ||
| Q4 24 | $-207.3M | $-138.3M | ||
| Q3 24 | $-266.8M | $-130.4M | ||
| Q2 24 | $-192.8M | $-128.2M | ||
| Q1 24 | $-108.5M | $-160.6M |
| Q4 25 | $-201.4M | — | ||
| Q3 25 | $-193.5M | — | ||
| Q2 25 | $-208.4M | — | ||
| Q1 25 | $-173.4M | — | ||
| Q4 24 | $-209.1M | $-139.5M | ||
| Q3 24 | $-267.8M | $-133.9M | ||
| Q2 24 | $-193.8M | $-130.6M | ||
| Q1 24 | $-108.8M | $-163.7M |
| Q4 25 | -10076.0% | — | ||
| Q3 25 | -12317.8% | — | ||
| Q2 25 | -9604.5% | — | ||
| Q1 25 | 438.1% | — | ||
| Q4 24 | -2318.5% | — | ||
| Q3 24 | -5984.4% | — | ||
| Q2 24 | -2425.5% | — | ||
| Q1 24 | -376.1% | — |
| Q4 25 | 246.9% | — | ||
| Q3 25 | 499.6% | — | ||
| Q2 25 | 185.9% | — | ||
| Q1 25 | -2.0% | — | ||
| Q4 24 | 20.3% | — | ||
| Q3 24 | 22.3% | — | ||
| Q2 24 | 12.1% | — | ||
| Q1 24 | 1.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -1.22× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -2.02× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
